Ravinder Heights Ltd files SAST disclosure for Serum Institute of India and PAC

What Ravinder Heights Ltd announced

Ravinder Heights Ltd (BSE: 543251) submitted a disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on 19 June 2026. The filing, received by the Bombay Stock Exchange, identifies Serum Institute of India Pvt Ltd and PAC as the entities that have acquired a substantial shareholding in Ravinder Heights Ltd.

The Regulation 29(2) filing is a statutory requirement whenever an entity acquires shares that cross the 1% threshold of the total paid‑up capital of a listed company, or when any subsequent acquisition pushes the holding beyond 5%, 10% or other prescribed limits. The filing serves to inform the market and existing shareholders of the change in shareholding structure.

"The Exchange has received the disclosure under Regulation 29(2) of SEBI (SAST) Regulations, 2011 for Serum Institute of India Pvt Ltd & PAC."

Parties involved

• Serum Institute of India Pvt Ltd – a leading vaccine manufacturer in India, known for its large domestic and export operations.
• PAC – the filing does not elaborate on the full legal name or nature of this entity; it is listed only as "PAC".

Both parties are now identified as substantial shareholders of Ravinder Heights Ltd, but the filing does not disclose the exact number of shares, the percentage of equity acquired, or the monetary value of the transaction.

Regulatory context

The SEBI (SAST) Regulations, 2011 aim to ensure transparency in take‑over situations and protect the interests of minority shareholders. Key provisions include:

• Mandatory disclosure of any acquisition that crosses the 1% threshold.
• Requirement to file a detailed offer document if the acquisition exceeds 25% of the voting rights.
• Obligation to obtain approvals from the board, shareholders, and, where applicable, the Competition Commission of India.

Ravinder Heights Ltd’s filing satisfies the immediate disclosure obligation; further regulatory steps will depend on the size of the shareholding and any subsequent actions taken by the acquirers.

Key facts at a glance

Why this matters for investors

The disclosure signals that two significant entities have taken a material stake in Ravinder Heights Ltd. While the exact size of the holding is not disclosed, the fact that a Regulation 29(2) filing was required indicates that the acquisition crossed at least the 1% threshold. Investors should monitor subsequent filings for:

• Updated shareholding percentages.
• Any offer documents if the acquirers move toward a full takeover.
• Board resolutions or shareholder meeting outcomes that may affect corporate strategy.

The filing itself does not imply any immediate operational changes, but it does place the company under heightened regulatory scrutiny and may affect future governance decisions.

Conclusion

Ravinder Heights Ltd complied with SEBI’s disclosure requirements by filing a Regulation 29(2) notice on 19 June 2026, naming Serum Institute of India Pvt Ltd and PAC as substantial shareholders. The filing does not reveal the exact share percentage or transaction value, and further regulatory approvals may be required if the holdings exceed higher thresholds. Investors should await additional disclosures for a clearer picture of the impact on the company’s ownership structure.